Why I Can't Stop Buying AbbVie Stock

AbbVie is presented as a value opportunity after a 7.03% year-to-date decline to $208.99, supported by a 3.19% dividend yield and a history of annual dividend increases. Full-year 2025 revenue rose 8.57% to $61.16 billion, with Skyrizi up 32.5% and Rinvoq up 29.5% in Q4 helping offset a 25.9% decline in Humira. Management guided 2026 adjusted EPS to $14.37-$14.57, implying roughly 14x forward earnings and a PEG of 0.476, while analysts’ consensus target is $249.

Analysis

ABBV is becoming less a binary Humira-exit story and more a quality-growth compounder with a visible cash-return floor. The second-order implication is that the market may continue to underwrite a “defensive pharma” multiple even as earnings growth re-accelerates, because the dividend and buyback capacity reduce downside volatility and keep a natural bid under the equity on weak tape. That matters in a rate-sensitive environment: if yields grind lower, ABBV can attract both income and growth buyers simultaneously, which is why pullbacks may keep getting monetized quickly.

The more important catalyst is not the dividend but the pace of franchise substitution. If Skyrizi/Rinvoq continue to outgrow the legacy decline through the next couple quarters, the market will likely stop treating ABBV as a patent-cliff recovery and start treating it as an immunology platform with operating leverage. That would force a multiple reset higher, especially because the current setup appears to embed skepticism around sustainability rather than near-term execution. The flip side is that any surprise acceleration in Humira erosion would hit sentiment disproportionately, because the bull thesis depends on the glidepath staying orderly through 2026.

The contrarian read is that consensus may be too anchored to headline trailing metrics and not enough on normalized earnings power. If forward EPS is even approximately on track, the stock screens cheap for a business with this level of cash generation and capital return visibility. The market is effectively pricing in execution risk without paying for duration, which creates asymmetry: limited downside unless the replacement engine breaks, but meaningful upside if guidance proves conservative again at the next print.

Near term, the Q1 update is the key volatility event. A clean print should reinforce the re-rating narrative, while any guidance wobble will probably be bought by yield-focused accounts unless the miss signals a structural issue in immunology share capture.

Key Decisions for Investors

• Long ABBV into the Q1 2026 earnings print on April 29, 2026; use a 3-6 month horizon and target a re-rating toward the low- to mid-220s if guidance is reaffirmed, with downside limited by the dividend and buyback support.
• Buy ABBV call spreads 1-2 months out around earnings to express upside with defined risk; structure for a post-print move higher if management confirms that replacement growth is still outpacing Humira decay.
• Pair trade: long ABBV / short a slower-growth large-cap healthcare peer with weaker patent visibility over the next 6-12 months; the relative-value edge is ABBV’s earnings acceleration versus names still stuck in ex-growth digestion.
• If ABBV gaps higher on earnings but does not materially raise the forward outlook, take profits on part of the position; the core risk is multiple compression if the market concludes the growth rate is already priced in.